10-Q: ALX Oncology Reports Q1 2025 Financial Results, Pipeline Adjustments Impacted by Clinical Trial Outcomes

ALX Oncology's Q1 2025 results reveal a net loss, pipeline prioritization, and strategic shifts following Phase 2 trial outcomes, alongside efforts to maintain Nasdaq listing compliance.

Summary

• ALX Oncology Holdings Inc. reported its financial results for the quarter ended March 31, 2025, showing a net loss of $30.8 million, compared to a net loss of $35.6 million for the same period in 2024.
• The company is focusing on its lead product candidate, evorpacept, and its EGFR-targeted ADC, ALX2004.
• Recent topline data from Phase 2 clinical trials ASPEN-03 and ASPEN-04 for evorpacept in combination with pembrolizumab for head and neck squamous cell carcinoma (HNSCC) did not meet primary endpoints, leading to a decision to discontinue this development path.
• The company received guidance from the FDA that ASPEN-06 Phase 2 trial data was not eligible for accelerated approval given the availability of ENHERTU, and will consider exploring development partnerships to advance this program in gastric cancer.
• ALX Oncology is planning to initiate a randomized Phase 2 clinical trial evaluating evorpacept in combination with trastuzumab and chemotherapy for HER2-positive metastatic breast cancer after prior treatment with fam-trastuzumab deruxtecan-nxki.
• The company is also planning to initiate a Phase 1b study evaluating evorpacept in combination with cetuximab and FOLFIRI for second-line metastatic colorectal cancer (CRC).
• Based on final data analysis, the company decided to discontinue evaluation of evorpacept in combination with enfortumab vedotin-ejfv (EV) in urothelial cancer, as the addition of evorpacept to EV did not meet the bar for improved efficacy.
• Research and development expenses decreased to $23.9 million from $31.7 million in the same quarter of the previous year, primarily due to reduced clinical and development costs.
• General and administrative expenses increased to $7.9 million from $6.0 million in the same period of the previous year, mainly due to severance costs from a reduction in workforce.
• As of March 31, 2025, ALX Oncology had cash, cash equivalents, and investments totaling $107.0 million, which is expected to fund operations into the fourth quarter of 2026.
• The company received a Nasdaq notice regarding non-compliance with the minimum bid price requirement and is assessing actions to regain compliance.
• A reduction in workforce of approximately 30% was implemented as part of a pipeline prioritization and cash preservation strategy.

Sentiment

Score: 4

Explanation: The document presents a mixed sentiment. While there's a decrease in net loss and a focus on promising programs, the discontinued trials and Nasdaq compliance issues weigh negatively. The company's financial runway provides some stability, but the overall outlook is cautiously optimistic.

Positives

• The net loss decreased from $35.6 million in Q1 2024 to $30.8 million in Q1 2025.
• The company has $107.0 million in cash, cash equivalents, and investments, expected to fund operations into Q4 2026.
• The company is planning to initiate Phase 2 trials for evorpacept in HER2-positive metastatic breast cancer and a Phase 1b study in metastatic colorectal cancer.
• Research and development expenses decreased by $7.8 million year-over-year.

Negatives

• The company reported a net loss of $30.8 million for Q1 2025.
• Development of evorpacept in combination with pembrolizumab for HNSCC is being discontinued after Phase 2 trials failed to meet primary endpoints.
• The FDA advised that ASPEN-06 data is insufficient for accelerated approval, necessitating a Phase 3 trial against ENHERTU.
• Evaluation of evorpacept in combination with enfortumab vedotin-ejfv (EV) in urothelial cancer has been discontinued due to lack of improved efficacy.
• General and administrative expenses increased by $1.9 million year-over-year.
• The company received a Nasdaq notice due to non-compliance with the minimum bid price requirement.

Risks

• Failure of future clinical trials to demonstrate safety and efficacy of product candidates.
• Delays in regulatory approvals or failure to obtain them.
• Inability to obtain and maintain patent protection for product candidates.
• Dependence on key personnel and the ability to attract and retain qualified employees.
• Reliance on third-party manufacturers for clinical supplies.
• Macroeconomic conditions and global economic environment, such as inflation, interest rate changes, trade and other global disputes and interruptions, economic downturns, bank failures or instability in the financial services sector, or geopolitical risks, disasters, and medical or public health crises.
• Potential delisting from the Nasdaq Global Select Market if compliance with listing requirements is not maintained.
• Volatility in the price of the company's stock.

Future Outlook

The company expects its existing cash, cash equivalents, and investments will be sufficient to fund its operating expenses and capital expenditure requirements into the fourth quarter of 2026. The company also has the ability to further utilize the ATM program.

Industry Context

ALX Oncology operates in the competitive immuno-oncology market, facing competition from major pharmaceutical and biotechnology companies developing therapies for cancer treatment. The company's strategic decisions, such as pipeline prioritization and seeking development partnerships, reflect the challenges and opportunities in this rapidly evolving field.

Comparison to Industry Standards

• The decision to discontinue certain clinical trials and focus on specific indications aligns with industry trends of optimizing resource allocation and prioritizing promising assets.
• The company's cash position and runway are critical in the context of biotech industry benchmarks, where funding is essential for advancing clinical programs.
• Comparable companies in the immuno-oncology space, such as Forty Seven (acquired by Gilead), Trillium Therapeutics (acquired by Pfizer), and others mentioned in the document, are also pursuing CD47-targeted therapies, highlighting the competitive landscape.
• The company's strategic decisions, such as pipeline prioritization and seeking development partnerships, reflect the challenges and opportunities in this rapidly evolving field.

Management Changes

Corporate Governance

Related Party Transactions

• The Company has several related-party agreements with Tallac Therapeutics, Inc., or Tallac, and with ScalmiBio, Inc., or ScalmiBio.
• During the three months ended March 31, 2025 and 2024 , the Company recorded $ 48,000 and $ 0.4 million , respectively, as R&D costs in relation to the collaboration agreement with Tallac, or the Tallac Collaboration Agreement.
• During the three months ended March 31, 2025 and 2024 , the Company made no milestone payment and $ 1.0 million milestone pa yment, respectively, as a result of selecting a development candidate, to the stockholders of ScalmiBio, including 31.7 %, or $ 0.3 million, to the Companys former Chief Executive Officer and former Chief Scientific Officer and President, and 63.5 %, or $ 0.6 million, to another employee of the Company.

Stakeholder Impact

• Shareholders: Stock price may be affected by clinical trial outcomes and Nasdaq compliance.
• Employees: Workforce reduction of approximately 30% was implemented.
• Patients: Pipeline adjustments may impact the availability of potential treatments.
• Collaborators: Strategic decisions may affect existing and future partnerships.

Next Steps

• Initiate a randomized Phase 2 clinical trial evaluating evorpacept in combination with trastuzumab and chemotherapy for HER2-positive metastatic breast cancer.
• Initiate a Phase 1b study evaluating evorpacept in combination with cetuximab and FOLFIRI for second-line metastatic colorectal cancer (CRC).
• Assess potential actions to regain compliance with Nasdaq's minimum bid price requirement.

Key Dates

Keywords

evorpacept, ALX2004, oncology, clinical trials, financial results, pipeline, FDA, HNSCC, HER2, urothelial cancer